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Highlights 
 
This is an important study after the publication of ISAT and BRAT for the 
management of aSAH, where coiling is generally believed to be superior, and is the 
first line treatment for aneurysm obliteration in many neurosurgical centres 
worldwide.  
 
ISAT study randomized aneurysms suitable for both coiling and clipping, while the 
data has since been generalized to the entire cohort of cerebral aneurysms including 
the wide neck, complex aneurysms. Currently, in many UK centres, over 90% of 
aneurysms are coiled, as the perception has been coiling is better, and every 
attempt should be made to coil aneurysms (even subtotally), with surgery only a last 
resort. We hope that our data will help to modify this viewpoint. 
 
In the current era of aSAH management, apart from patients’ admission status, SAH 
blood load and the development of DCI, treatment modality with either coiling or 
clipping was not associated with poor outcome difference at 6 months. 
 
The key message is that in the event of any perceived difficulty with coiling, then one 
can comfortably offer clipping without the concern for a long-term disadvantage for 
clipping. The short-term advantages for coiling are still very apparent. 
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 Abstract 
 
Introduction: The management of aneurysmal SAH has changed 
dramatically in the last few decades with the publication of a few major studies 
including The International Cooperative Study on the Timing of Aneurysm 
Surgery Study, International Subarachnoid Aneurysm Trial (ISAT). The aim of 
this study is to analyse the outcome of patients with aSAH based on a 
contemporary series, identify the risk factors for poor outcome, and focusing 
on patients with good grades aSAH (to match the ISAT cohort). 
 
Method: Baseline demographic and outcome data (mRS) was available on 
the 803 patients recruited from the STASH (Simvastatin in aneurysmal 
subarachnoid haemorrhage) trial for post hoc analysis, using chi square test 
or two-sample t-test. Logistic regression analysis was performed to assess 
the risk factors for poor outcome at 6 months. Propensity matched analysis 
comparing coiling and clipping, and subgroup analysis of good grades 
patients (WFNS I-II) were also performed. 
 
Result: Logistic regression analysis showed that the treatment modality (i.e 
coiling or clipping) was not associated with poor outcome at 6 months 
(p=0.839). The risk factors associated with poor outcome at 6 months were 
poor admission WFNS grade (p<0.0001), Fisher grade on initial CT scan 
(p=0.013), and the development of delayed cerebral ischaemia (DCI) 
(p<0.0001). Subgroup analysis for good grades patients only showed 82% of 
patients post coiling, and 78% of patients post clipping were classed as good 
outcome at 6 months (p=0.181). 
 
Conclusion: In the current era of aSAH management, apart from patients’ 
admission status, SAH blood load and the development of DCI, treatment 
modality with either coiling or clipping was not associated with poor outcome 
difference at 6 months. 
 
 
 Introduction 
 
The management of aneurysmal subarachnoid haemorrhage has changed 
dramatically in the last few decades. The International Cooperative Study on 
the Timing of Aneurysm Surgery was the first large-scale, prospective, 
observational study to look at the issue of timing, and they also addressed 
factors that influenced outcome at 6 months stratified by Glasgow Outcome 
Scale (GOS). With 3521 patients recruited out of 8879 patients with SAH 
between 1980 and 1983,1,2 75% of those admitted within 3 days were in good 
condition, with a 58% good recovery at 6 months, and 25% death rate. Initial 
bleed, vasospasm and rebleeding were the major causes of death and 
disability. A number of key prognostic factors identified included admission 
Glasgow coma scale (GCS) (75% who were alert on admission had good 
recovery, compared to 11% who were comatose) and age (only 26% of those 
between 70 and 87 years had a good outcome). The results also showed that 
at 6 months, 69% who had surgery had good outcome, with alert patients 
preoperatively had a favourable prognosis if operated between days 0-3 or 
after day 10. Subgroup analysis then showed that 71% versus 62% of 
patients operated on between days 0-3 versus days >10 had good recovery  
(p<0.01).3 
 
This study confirmed that older, poor-grade patients with pre-existing medical 
conditions have a bleak prognosis. It also prompted an international change 
on the timing to early surgery for good grade patients. 
 
The International Subarachnoid Aneurysm Trial (ISAT)4-6 was the first large 
scale randomized trial of endovascular coiling vs. microsurgical clipping of 
ruptured aneurysms. 2143 patients from the initial 9559 patients screened 
were randomized, and a statistically significant outcome difference (using 
mRS) of 7% was found at one year in favour of coiled patients. Of the enrolled 
patients, 88% were good grades (WFNS class I or II), 95% were anterior 
circulation aneurysm, and 90% were smaller than 10mm. The trial result has 
since been generalized to most patients with aSAH in many parts of the world, 
with over 90% of cerebral aneurysms managed by endovascular coiling in 
many UK neurosurgical centres. 7,8  
 
With technological advances over the last two decades, changing practice in 
the management of aSAH patients, increasing proportion of patients coiled, 
and improvements in both microsurgical and endovascular techniques there is 
a need for to reassess the factors determining patients’ outcome in a 
contemporary series. 
 
The Simvastatin in aneurysmal subarachnoid haemorrhage (STASH) trial was 
an international, multicentre, parallel group, double-blinded, randomized 
phase 3 trial. It was designed to determine whether simvastatin 40mg could 
improve the long-term outcome of patients with aSAH. 803 patients were 
recruited from 35 neurosurgical units (23 in the UK and 12 non-UK sites) 
between January 2007 and February 2013.  Details of the study are described 
in a previous paper. 9 
 
The aim of the present study was to analyse the STASH cohort to identify risk 
factors for poor outcome and to compare the outcome between those 
managed by neurosurgical clipping and endovascular coiling. focusing on 
patients with good grade aSAH (in line with the ISAT cohort). 
 
Materials and Methods 
 
Trial design and participants 
Baseline demographic and outcome data were available on the 803 patients 
recruited from the STASH trial for post hoc analysis.  
 
Inclusion criteria were radiological confirmatory evidence of an aneurysmal 
subarachnoid haemorrhage (by digital subtraction angiography [DSA], CT 
angiography [CTA], or magnetic resonance angiography [MRA], age 18-65 
years and the presentation less than 96 hours from ictus. Exclusion criteria 
were patient taking statin therapy at presentation, pregnancy, no reasonable 
prospect of survival, known renal or hepatic impairment, patient not fully 
independent before bleed, strong suspicion of drug or alcohol misuse, patient 
unlikely to be amenable to follow-up, patient taking warfarin-type drugs, 
patient taking contraindicated medication (amiodarone, amlodipine, verapamil, 
or potent CYP3A4 inhibitors), or suspected additional life-threatening disease. 
 
Of the 803 patients, coiling only was performed in 513 patients (64%), clipping 
only in 254 patients (32%), both coiling and clipping in 14 patients (2%), 22 
patients had no treatment or were treated by other means. For the purpose of 
this post-hoc analysis, patients with single modality treatment of coiling or 
clipping were included, i.e. 767 patients. 
 
Outcomes 
The primary outcome was the distribution of modified Rankin Scale (mRS) at 
6 months by means of a standardized questionnaire. Secondary outcomes 
were death at 6 months, delayed ischaemic deficit, delayed ischaemic deficit 
requiring rescue therapy, admission to an intensive care unit, incidence of 
sepsis, discharge destination, quality of life as measured by the SF-36 (short 
form health survey questionnaire) at 6months. These secondary outcomes 
were preselected to provide supportive evidence related to the primary 
outcome. We defined delayed ischaemic deficit as a deterioration of two or 
more points on the Glasgow Coma Scale or the development of new 
neurological deficit that could not be attributed to any other cause including 
sepsis. We defined sepsis when clinical symptoms (eg raised temperature, 
raised white cell count, tachycardia, or raised respiratory rate) had 
microbiological confirmation. Use of hypervolaemic and inotropic rescue 
treatment was that adopted by every centre and did not follow any prescribed 
definition. 
 
Statistical Analysis 
Conventional dichotomy of favourable mRS (0-2) versus unfavourable mRS 
(3-6) was used for outcome analysis. 
 
Comparison table of the baseline characteristics of patients who underwent 
coiling or clipping was shown. Statistical analysis was performed using chi 
square test or two-sample t-test as appropriate, to identify risk factor 
associated with poor outcome at 6 months (primary outcome). Logistic 
regression analysis was performed to correct for confounding factors to 
further assess the risk factors for poor outcome at 6 months. Results are 
presented as an adjusted common odds ratio (OR) with the corresponding 
95% confidence interval (CI), with values of the common OR more than 1 
indicating risk factors associated with poor outcome. 
 
Propensity Matched Analysis 
To compare the outcomes of patients who had aneurysms secured by 
endovascular coiling with those who underwent microsurgical clipping a 
propensity matched analysis was undertaken. This procedure essentially 
matches patients treated with coiling or clipping who have similar baseline 
factors to mimic, as closely as possible, the balanced groups that would be 
expected had the patients been randomly allocated to their respective 
aneurysm treatment. 
 
The propensity score was constructed using logistic regression of aneurysm 
treatment (clipping vs. coiling) against age, sex, admission WFNS grade, 
Fisher grade, need for mechanical ventilation on admission, aneurysm 
location, and randomization group (control vs. statin). An optimal matching 
algorithm then generated a cohort with equal number of patients treated with 
coiling and clipping with balanced baseline covariates. Outcomes were then 
compared between the matched groups. All procedures were performed in R 
(v.3.2.3) using the MatchIt package.10 
 
Subgroup Analysis 
In order to simulate the baseline demographics of the ISAT cohort using this 
dataset, further analysis focused on patients with good grade aSAH (WFNS 
grade I and II) was performed to compare the treatment outcome between 
those managed by neurosurgical clipping and endovascular coiling. Baseline 
demographics, primary and secondary outcome, and 6 months quality of life 
score were compared using chi-square test, two-sample t-test as appropriate. 
 
Result 
 
80% of patients managed by endovascular coiling were good grade on 
admission (WFNS I, II) compared to 60% in the neurosurgical arm, figure 1. 
More patients in the clipping arm had intraparenchymal haemorrhage (23%) 
compared 9% in the coiled group. The remaining baseline characteristics 
were well matched (Table 1). 
 
Good outcome at discharge was observed in 67% of patients post coiling 
compared to 47% in the post-clipping group (p=0.0001) (Figure 1B).  
 
Comparison of outcome at 6 months is shown in Table 2. Apart from the 
location of aneurysms, all other factors (age, WFNS grade, Fisher grade, 
treatment used, ictus to treatment time, delayed cerebral ischaemia, sepsis) 
show statistically significant association with poor outcome. 32% of older 
patients (age over 50 years) (120/400) were associated with poor outcome 
compared to 25% (91/382) of younger patients (age 18-50 years) (p=0.028). 
53% of patients with poor grade SAH had poor outcome at 6 months, 
compared to 19% of patients with good grade SAH (p<0.0001). 34% of 
patients who underwent clipping had poor outcome compared to 25% of 
patients who underwent coiling (p=0.017). 
 
To address the issue of confounding factors, logistic regression analysis was 
performed (Table 3). The risk factors which were associated with poor 
outcome were poor WFNS grade on admission, Fisher grade on initial CT 
scan and the development of delayed cerebral ischaemia. Treatment modality 
was not shown to be associated with poor outcome at 6 months (p=0.839). 
 
Propensity Matched analysis 
 
Using the optimal propensity score matching procedure a subgroup of 498 
patients (249 coiled and 249 clipped) were selected.  Age, sex, admission 
WFNS grade, Fisher score, and proportion of patients ventilated were not 
significantly different between the matched groups (Table 4). However, the 
distribution of aneurysms could not be fully matched due to the larger number 
of middle cerebral aneurysms that were clipped. Nonetheless, there was no 
significant difference in the incidence of confirmed DIND or sepsis between 
the matched groups. Moreover, 6 month mRS scores and overall favourable 
neurological outcome was not significantly different between coiling and 
clipping (Table 4). 
 
Subgroup analysis 
 
560 patients were good grade (WFNS I & II) on admission. Of these, 408 
(73%) had endovascular coiling and 152 (27%) had neurosurgical clipping. 
Baseline clinical and demographic characteristics were shown in Table 5. The 
proportion of WFNS grade I and II, Fisher grade for SAH blood load on CT 
scan, and imaging modality was well matched in both groups. The distribution 
of aneurysms selected for coiling and clipping varied. The anterior 
communicating artery aneurysms were most commonly coiled (36%) 
compared with the middle cerebral artery aneurysms most commonly treated 
surgically (36%). Time from ictus to treatment of aneurysms was similar for 
both groups. 
 
Immediate procedural related problems or complications (intraoperative 
rupture, uncontrolled brain swelling, major vessel occlusion, thromboembolic 
event) were low in both groups, and no statistically significant differences 
were detected. 
 
The rate of confirmed delayed cerebral ischaemia was lower in patients who 
had endovascular coiling (11%) compared to patients who had neurosurgical 
clipping (21%), (p=0.001). There was also a lower risk of developing sepsis 
for patients post coiling (13%) compared to clipping (23%), (p=0.001). A lower 
proportion of patients post coiling were admitted to HDU/ITU (41% vs 53%, 
p=0.012), needed extended hypervolaemic therapy (16% vs 30%, p=0.001), 
or required inotropic support (17% vs 30%, p=0.001). The rate of patients 
needing other rescue therapy for delayed cerebral ischaemia (angioplasty, 
intra-arterial papaverine or nimodipine) was similar between the two groups, 
(Table 6).  
 
The mean length of hospital stay for coiling group of patients was 16.3 days 
(range 5-119 days), compared to patients who underwent clipping 18.9 days 
(range 4-120 days). 74% of patients managed by endovascular coiling was 
discharged home, compared to 66% of surgical patients, but this difference is 
not statistically significant (p=0.110). 
 
At discharge, favourable outcome (mRS 0-2) was observed in 76% of post 
coiled patients, compared to 66% of patients post clipping (p=0.06, Table 6, 
Figure 2). This rate subsequently improved. At 6 months 82% of patients post 
coiling, and 78% of patients post clipping were classed as good outcome 
(p=0.181, Table 6, Figure 2). At 6 months, 3% of post coiling patients, and 5% 
of post clipping patients had died. 
 
SF-36 at 6 months was available for 87% of patients in both treatment arms 
(356/408 for coiled patients, and 132/152 for clipped patients). The mean 
physical score, mental score and overall scores were lower in the coiling arm. 
The differences noted were statistically significant, (Table 6). 
 
Discussion 
 
Initial analysis showed that older age, poor WFNS grade, high Fisher grade 
on initial CT head scan, treatment used (clipping), ictus to treatment time, 
development of delayed cerebral ischaemia and sepsis were associated with 
poor outcome at 6 months post aneurysmal SAH in this post-hoc study using 
the STASH trial cohort recruited from 35 neurosurgical units (23 in the UK and 
12 non-UK sites) between January 2007 and February 2013. However, after 
correcting for confounding factors using logistic regression analysis, WFNS 
grade, fisher grade on CT scan and the development of delayed cerebral 
ischaemia remained highly significant risk factors associated with poor 
outcome. Several studies have also confirmed the important role of WFNS 
grade, initial CT fisher grade in determining patients’ outcome post aSAH. 
1,2,11-14 
 
There is a trend towards worse outcome for older patients (over 50 years old), 
(odds ratio 1.342, 95% confidence interval 0.947-1.904, p=0.098) but not 
statistically significant as previously shown by other studies.1,2,15 Such a 
finding is not unexpected as our cohort excluded patients over 65 years, who 
have been shown on many previous studies to be associated with very poor 
outcome.1,2. Previous studies showed that level of consciousness, WFNS 
grade, rate of rebleeding, rate of hydrocephalus worsened with advancing 
age.15 However, more recent studies showed that over 75 years as the critical 
age for poor outcome,16,17 and there are now increasing evidence of 
subgroups of very elderly patients being treated aggressively with good long 
term outcome.18,19 
 
Previous studies1,2,20 showed that the timing of surgery was associated with 
better outcome and prompted an international change on the timing to early 
surgery for good grade patients. The results showed that at 6 months, 69% 
who had surgery had good outcome, with alert patients preoperatively had a 
favourable prognosis if operated between days 0-3 or after day 10. Subgroup 
analysis from the North American cohort then showed that 71% versus 62% 
of patients operated on between days 0-3 versus days >10 had good recovery  
(p<0.01).3 Nowadays, combined with the options of endovascular treatment, 
most patients (693/749, 93%) in our study had aneurysms secured early on 
(within 96 hours post ictus), a very different practice to the era during The 
International Cooperative Study on the Timing of Aneurysm Surgery. 
Inherently, there are many confounding factors that determine the timing of 
surgery or coiling (>96hours) for the 7% of patients in this study, i.e. those 
who undergo delayed treatment are generally limited by other medical factors. 
Therefore it was not surprising that the timing of treatment was shown to be 
statistically significant predictor for poor outcome initially, with the effect lost 
after correction for confounding factors. 
 
Contrary to the ISAT4-6 study from 2002, which suggested endovascular 
coiling was preferable to neurosurgical clipping, this post hoc analysis of a 
contemporary series of patients from the STASH trial data showed no 
statistically significant differences between clipping and coiling at 6 months, 
using both propensity matched analysis and subgroup analysis of good grade 
patients only to simulate the ISAT cohort. Furthermore subgroup analysis 
showed the outcome differences noted at discharge were lost in patients with 
good grade aSAH managed by either treatment modality. 
 
In the ISAT study, the ictus to treatment time was different between the two 
treatment modalities (mean 3.1 days for coiling, 3.7 days for clipping) and 
hence more patients suffered aneurysmal rebleed prior to treatment.6,21 In this 
study, time to treatment was comparable in both groups. This, coupled with 
modern day technology incorporating better microscopic visualization, the use 
of intraoperative indocyanine green (ICG) and neurosurgical clipping now 
performed by expert neurovascular neurosurgeon, may account for the 
improvement in outcome observed. 
 
In comparison to the ISAT4-6 and BRAT22,23 study (Table 7), the proportion of 
patients with good outcome has increased for both treatment modalities. 
ISAT4-6 reported 76% of patients post coiling, and 69% post clipping had good 
outcome at 1 year, compared to 81% and 78% respectively in our cohort at 6 
months. Such improvement is promising, considering that when ISAT was 
performed, only a select group of aneurysms were included (88% were good 
grades (WFNS class I or II), 95% were anterior circulation aneurysm, and 
90% were smaller than 10mm). Likewise the BRAT22,23 study demonstrated a 
similar outcome; but with only 49% of good grade patients and with a greater 
proportion of posterior circulation aneurysms, they could still achieve a very 
comparable outcome to the ISAT study (Table 7). In the current era, when 
interventional neuroradiologists are treating the more complex and 
challenging aneurysms, to retain the same results is very reassuring. The 
more remarkable finding is that the results for neurosurgical clipping have 
improved even further, aided by the advent of technology, we are now in an 
era where good outcome could be comparable to endovascular treatment. 
 Our subgroup analysis showed that patients who underwent neurosurgical 
clipping had a higher risk of developing delayed cerebral ischaemia, although 
this finding was not supported by the propensity score analysis conducted. 
Nevertheless, a recent meta-analysis showed that delayed cerebral ischemia 
was more common after clipping (OR 1.43; 95% CI 1.07-1.91), but ischemic 
infarct, shunt-dependent hydrocephalus, and procedural complications did not 
differ significantly between coiling and clipping.24 Provided that patients are 
adequately managed, the development of delayed cerebral ischaemia in 
patients who had clipping did not translate into longer-term poor outcome. 
Despite the use of nimodipine, which has been shown to reduce the risk of 
delayed cerebral ischaemia, about 25% of patients still developed it post 
aSAH.25,26 The overall level of delayed cerebral ischaemia (16%) in our cohort 
is lower than previously reported, and this could be attributed to more aSAH 
patients being treated by coil embolisation (DIND rate 21% in patients post 
clipping, and 11% post coiling). 
 
The propensity-score matching analysis demonstrates that patients of similar 
age, sex, and severity of presenting haemorrhage (based on WFNS grade 
and Fisher score) have a comparable risk of developing delayed ischaemic 
deficits irrespective of the modality chosen to secure their aneurysm.  
Similarly, neurological outcome at six months amongst the matched groups 
was not dependent on whether the patient was clipped or coiled.  These 
findings do not imply that clipping and coiling are equivalent or 
interchangeable for all aneurysms. The inference should be that current 
selection criteria in determining which patients are best clipped or coiled result 
in equally good outcomes for both groups and there remains a clear role for 
both modalities. Despite the many advantages of propensity score matching 
analysis, one of the limitation is that it only accounts for observed covariates, 
and hidden bias could remain or be exaggerated after matching.27 Therefore 
propensity-score matching is still not a substitute for randomization. 
 
Good grade patients who were coiled experienced a lower SF36 score in 
terms of physical, mental & overall wellbeing. Such differences could be 
related to the psychological worry related to the longer term follow up required 
for the surveillance of these aneurysms to ensure they remaining static. 
Conversely, in our experience, most patients who underwent neurosurgical 
clipping could be generally reassured of complete aneurysm obliteration. 
 
Coiling or clipping should not be perceived as competing treatment modalities 
for securing cerebral aneurysms. They are complementary as both treatments 
have different roles in the management of aSAH. In the event of aneurysms 
suitable for both treatment modalities, coiling was shown to have better 
outcome by 7% according to the ISAT study, so endovascular treatment 
should be the preferred treatment. However in patients with cerebral 
aneurysms with anatomical configuration either less optimal or unsuitable for 
endovascular treatment, clipping should be offered as the first treatment 
modality. As shown in this paper, good grade patients do not experience a 
significant disadvantage post clipping, therefore neurosurgeons should not 
perceive clipping as the last resort only after attempted coiling. 
 
In order to ensure that we deliver the highest standard of care for our patients, 
we need to continue to improve and strive to minimize technical related 
complications. With an increasing number of cerebral aneurysms being 
secured by endovascular coiling, training for the next generation of 
neurovascular surgeons can be challenging. However, with the advent of 
modern technology, realistic simulation surgery is a crucial tool for training. 
Several studies have shown that complex cases performed by high volume 
large centres achieved better outcome than low volume smaller units.28-30 
Therefore centralisation of neurovascular centres where neurosurgical 
clipping cases are performed in selected centres would increase the 
caseload, maintain surgeons’ expertise and enhance training opportunities. 
 
This is a post-hoc analysis from STASH study, which was not designed 
primarily to look at the outcome difference between the two treatments 
modality, as such is a limitation of the study. Furthermore, the rate of 
aneurysms recurrence and retreatment were not part of the STASH trial 
protocol, and therefore not available for analysis. However, several changes 
to the management of aSAH in the current era and important findings were 
borne out in this paper. 
 
With regards to the longer term outcomes, many studies including large scale 
randomized controlled trials (ISAT and BRAT) showed that retreatment and 
rebleeding risks were higher in the endovascular group. In BRAT study, with 
up to 6 years follow up, overall retreatment rates were 16.4% for coiling and 
4.6% for clipping (p<0.0001).31 In the ISAT study with up to 18 years follow 
up, incidence of recurrent SAH was one in 641 patient-years for coiling, 
versus one in 2041 patient-years for clipping.32 However, the ISAT study also 
confirmed the long term durability of endovascular treatment. 
 
Conclusion 
 
In the current era of aSAH management, apart from patients’ admission 
status, SAH blood load and the development of DCI, treatment modality with 
either coiling or clipping was not associated with poor outcome difference at 6 
months. In this post-hoc study of selective patients involved in the STASH 
trial, the effect of age and timing from ictus to intervention was lost after 
correction for confounding factors, a finding not unexpected as elderly 
patients (over 65 years) were excluded, and over 90% of patients had their 
aneurysms secured early on (within 96 hours post ictus). 
 
Within the limit of a posthoc analysis, this study also showed good grade 
patients managed with either coiling or clipping experienced no difference in 
outcome at discharge or at 6 months, including physical and mental wellbeing. 
Endovascular coiling and neurosurgical clipping both have a role to play in the 
management of subarachnoid haemorrhage.   
 
ISAT study randomized aneurysms suitable for both coiling and clipping, while 
the data has since been generalized to the entire cohort of cerebral 
aneurysms including the wide neck, complex aneurysms. Currently, in many 
UK centres, over 90% of aneurysms are coiled, as the perception has been 
coiling is better, and every attempt should be made to coil aneurysms (even 
subtotally), with surgery only a last resort. We hope that our data will help to 
modify this viewpoint. 
 
The key message is that in the event of any perceived difficulty with coiling, 
then one can comfortably offer clipping without the concern for a long-term 
disadvantage for clipping. The short-term advantages for coiling are still very 
apparent. 
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Figure 1. Distribution of scores for the whole cohort of STASH patients 
stratified by treatment modalities. (A) WFNS admission grade. (B) mRS at 
discharge. (C) mRS at 6 months. (mRS= modified Rankin Scale) 
 
Figure 2. Distribution of scores for the good grade aSAH patients stratified by 
treatment modalities. (A) WFNS admission grade. (B) mRS at discharge. (C) 
mRS at 6 months. (mRS= modified Rankin Scale) 
 
 
 Clipping  Coiling  p-value 
 (n=254)  (n=513)   
      
UK participants 189 (29%)  456 (71%)  <0.0001 
Non-UK participants 65 (53%)  57 (47%)   
Mean age (Range), yrs 50 (20-69)  50 (20-65)  N.S 
      
Male /Female 93/161  149/364  0.034 
      
Ethnic origin      
White 213(84%)  479 (93%)  <0.00001 
Asian 19 (7%)  17 (3%)   
Black 4 (2%)  8 (2%)   
Hispanic 17 (7%)  5 (1%)   
Other 1(<1%)  4 (1%)   
      
WFNS SAH grade      
I 98 (39%)  271 (53%)  <0.00001 
II 54 (21%)  137 (27%)   
III 22 (9%)  9 (2%)   
IV 50 (20%)  53 (10%)   
V 30 (12%)  43 (8%)   
 
Motor deficit 
 
53 (21%) 
  
42 (8%) 
 
 
 
<0.00001 
Cranial nerve deficit 31 (12%)  40 (8%)  0.047 
Ventilated 64 (25%)  94 (18%)  0.026 
      
Fisher grade      
1 3 (1%)  11 (2%)  0.008 
2 26 (10%)  82 (16%)   
3 74 (29%)  179 (35%)   
4 151 (59%)  241 (47%)   
Intraparenchymal haemorrhage 58 (23%)  48 (9%)  <0.00001 
Intraventricular haemorrhage 94 (37%)  175 (34%)  0.429 
Subdural haemorrhage 8 (3%)  9 (2%)  0.216 
Cerebral infarct 3 (1%)  2 (<1%)  0.200 
Hydrocephalus 31 (12%)  80 (16%)  0.209 
      
Imaging modality      
MRA 2 (1%)  8 (2%)  0.375 
CTA 200 (79%)  386 (75%)  0.283 
DSA 69 (27%)  180 (35%)  0.027 
      
Location of aneurysm      
ACoA 68 (27%)  179 (35%)  <0.0001 
PCoA 46 (18%)  137 (27%)   
ICA 13 (5%)  52 (10%)   
MCA 110 (43%)  60 (12%)   
Posterior circulation 12 (5%)  60 (12%)   
Other 5 (2%)  25 (5%)   
      
Mean time ictus to Tx (range)days 1.8 (0-17)  1.6 (0-10)  N.S 
      
Table 1. Baseline clinical and demographic characteristics, stratified by treatment modality 
Table 1
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 Good outcome at 6 
months 
Poor outcome at 6 
months 
p value 
 mRS 0-2  mRS 3-6   
 n=538  n=211   
Age of patients     0.028 
18-50 years 280 75% 91 25%  
>50 years 258 68% 120 32%  
      
WFNS grade on admission    <0.0001 
1-2 442 81% 104 19%  
3-5 96 47% 107 53%  
      
Fisher Grade on admission    <0.0001 
1-2 106 88% 14 12%  
3 192 79% 51 21%  
4 240 62% 146 38%  
      
Aneurysm location     0.576 
Anterior circulation 474 72% 184 28%  
Posterior circulation 49 73% 18 27%  
Other 15 63% 9 37%  
      
Treatment     0.017 
Clipped only 165 66% 85 34%  
Coiled only 373 75% 126 25%  
      
      
Ictus to treatment (hours)    0.008 
0-24 47 58% 34 42%  
25-48 239 73% 89 27%  
49-96 216 76% 68 24%  
>96 36 64% 20 36%  
      
Delayed cerebral 
ischaemia 
61 49% 64 51% <0.0001 
No DCI 477 76% 147 24%  
      
Sepsis 101 54% 86 46% <0.0001 
No 437 78% 125 22%   
Table 2. Factors determing 6 months outcome 
Table 2
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Variable Coefficient Standard error p value Odds ratio 95% confidence interval 
      Age >50 years 0.295 0.178 0.098 1.342 0.947 - 1.904 
WFNS grade (3-5) 1.133 0.204 <0.0001 3.106 2.082 - 4.633 
CT Fisher grade 0.347 0.140 0.013 1.414 1.075 - 1.861 
Clipping 0.038 0.189 0.839 0.963 0.666 - 1.391 
Delayed cerebral ischaemia 0.921 0.225 <0.0001 2.512 1.618 - 3.900   
Table 3. Binary logistic regression analysis for risk factors associated with poor outcome (mRS 3-6) at 6 months.  
Table 3
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 Coiling Clipping  
    
N 249 249  
    
Age (years, mean [SD] 49.4 [9.4] 49.9 [10.3] P=0.748 
    
Sex (% female) 61.8 63.9 P=0.711 
    
WFNS Grade (%)   P=0.107 
I 41.8 38.6  
II 23.7 21.3  
III 3.2 8.8  
IV 18.1 19.7  
V 13.3 11.6  
    
Fisher Grade   P=0.961 
1 1.2 1.2  
2 9.2 10.4  
3 20.1 28.5  
4 59.4 59.8  
    
Ventilated (%) 26.9 24.9 P=0.682 
    
Aneurysm Location (%)   P<0.001 
ACoA 41.4 26.9  
PCoA 22.9 17.7  
ICA 5.6 4.8  
MCA 22.9 43.8  
Posterior 5.2 4.8  
Other 2.0 2.0  
    
Delayed Ischaemic Deficit (%) 18.9 23.3 P=0.272 
Sepsis (%) 25.7 33.7 P=0.062 
    
mRS at 6 months (%)   P=0.957 
0 19.7 20.5  
1 28.9 27.3  
2 19.7 18.1  
3 11.6 14.9  
4 5.2 5.2  
5 3.6 2.8  
6 11.2 11.2  
    
Good outcome (%) 68.3 65.9 P=0.634 
    
 
 
Table 4.  Comparison of propensity-score matched treatment groups between coiling and 
clipping. 
Table 4
Click here to download Table(s): Table 4 Propensity matched analysis.docx
Good grade aSAH only Clipping  Coiling  
 (n=152)  (n=408)  
     
UK participants 115 (24%)  368 (76%)  
Non-UK participants 37 (48%)  40 (52%)  
Mean age (years) (Range) 49(20-66)  50(20-65)  
Male sex 52 (34%)  111 (27%)  
     
Ethnic origin     
White 132 (87%)  384 (94%)  
Asian 12 (8%)  14 (3%)  
Black 2 (1%)  4 (1%)  
Hispanic 6 (4%)  3 (1%)  
Other 0  3 (1%)  
     
WFNS SAH grade     
I 98 (64%)  271 (66%)  
II 54 (36%)  137 (34%)  
Motor deficit 5 (3%)  10 (2%)  
Cranial nerve deficit 11 (7%)  17 (4%)  
Ventilated 7 (5%)  15 (4%)  
     
Fisher grade     
1 3 (2%)  11 (3%)  
2 24 (16%)  80 (20%)  
3 59 (39%)  160 (39%)  
4 66 (43%)  157 (38%)  
Intraparenchymal haemorrhage 14 (9%)  28 (7%)  
Intraventricular haemorrhage 42 (28%)  116 (28%)  
Subdural haemorrhage 1 (1%)  6 (1%)  
Cerebral infarct 2 (1%)  2 (1%)  
Hydrocephalus 9 (6%)  37 (9%)  
     
Imaging modality     
MRA 1 (1%)  5 (1%)  
CTA 113 (74%)  305 (75%)  
DSA 50 (33%)  149 (37%)  
     
Location of aneurysm     
ACoA 45 (30%)  144 (36%)  
PCoA 37 (24%)  111 (27%)  
ICA 10 (7%)  41 (10%)  
MCA 54 (36%)  45 (11%)  
Posterior circulation 5 (3%)  48 (12%)  
Other 1 (1%)  19 (5%)  
     
Mean time, ictus to Tx (days) (range) 1.8 (0-17)  1.6 (0-10)  
     
     
     
     
Table 5. Baseline demographic characteristics for good grade patients, stratified by the 
treatment modality  
Table 5
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Good grade aSAH only Clipping  Coiling  p value 
 (n=152) 
 
 (n=408)   
Immediate procedural problems 5 (3%)  21 (5%)  0.353 
Intraprocedure bleed 1 (1%)  5 (1%)  0.562 
Uncontrolled swelling 1 (1%)  2 (1%)  0.809 
Major vessel occlusion 2 (1%)  4 (1%)  0.732 
Thromboembolic event 5 (3%)  5 (1%)  0.101 
Other event 13 (9%)  25 (6%)  0.310 
      
Suspected delayed ischaemia 42 (28%)  65 (16%)  0.002 
Confirmed delayed ischaemia 32 (21%)  43 (11%)  0.001 
Drop in GCS 37 (24%)  64 (16%)  0.018 
Focal deficit 29 (19%)  62 (15%)  0.268 
Proven radiological infarct 27 (18%)  37 (9%)  0.004 
      
Other causes of deterioration      
Sepsis 36 (24%)  51 (13%)  0.001 
Epilepsy 3 (2%)  8 (2%)  0.992 
Hypoxia 1 (1%)  5 (1%)  0.562 
Rebleed 1 (1%)  6 (1%)  0.441 
Hydrocephalus (needing EVD) 15 (10%)  57 (14%)  0.197 
Other 14 (9%)  27 (7%)  0.295 
      
Rescue therapy      
Extended hypervolaemic therapy 45 (30%)  67 (16%)  0.001 
Inotropic support 45 (30%)  70 (17%)  0.001 
Angioplasty 4 (3%)  5 (1%)  0.239 
Intrarterialpapeverine or nimodipine 1 (1%)  7 (2%)  0.348 
Steroids 9 (6%)  23 (6%)  0.898 
ITU or HDU stay 81 (53%)  169 (41%)  0.012 
ITU or HDU mean stay, days (range) 10 (1-29)  9 (1-81)   
 
Mean length of hospital stay, days (range) 18.9 (4-120)  16.3 (5-119)  0.088 
 
Discharge destination     0.110 
Home 101 (66%)  303 (74%)   
Non-neurosurgical ward 21 (14%)  49 (12%)   
Rehabilitation 21 (14%)  32 (8%)   
Other  2 (1%)  11 (3%)   
Died 7 (5%)  11 (3%)   
      
Modified Rankin Scale score at discharge    0.060 
mRS 0 32 (21%)  90 (22%)   
mRS 1 39 (26%)  158 (39%)   
mRS 2 29 (19%)  62 (15%)   
mRS 3 28 (18%)  47 (12%)   
mRS 4 12 (8%)  28 (7%)   
mRS 5 5 (3%)  10 (2%)   
mRS 6 7 (5%)  11 (3%)   
Table 6
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Table 6. Comparison of outcome measures for patients with WFNS Grades 1 
and 2 on admission 
      
Modified Rankin Scale score at 6 months    0.181 
mRS 0 47 (31%)  90 (23%)   
mRS 1 43 (29%)  147 (37%)   
mRS 2 27 (18%)  88 (22%)   
mRS 3 19 (13%)  47 (12%)   
mRS 4 4 (3%)  10 (3%)   
mRS 5 2 (1%)  3 (1%)   
mRS 6 8 (5%)  11 (3%)   
      
SF-36 at 6 months      
Number of patients 132  356   
Physical score mean (range) 64.8 (10-100)  57.3 (4-100)  0.001 
Mental score mean (range) 64.2 (11-100)  58.6 (2-100)  0.028 
Overall score mean (range) 64.8 (10-100)  59.3 (4-100)  0.026 
 
Good outcome at 1 year/6months WFNS/HH Grade at presentation Aneurysm location 
Trial Coil (%) Clip (%) 
 
1-2 (%) 3-5 (%) 
 
Ant (%) Post (%) 
         ISAT 76 69 
 
88 12 
 
97 3 
BRAT 79 69 
 
49 51 
 
83 17 
         STASH - post hoc (good grade) 81 78 
 
100 
  
91 9 
STASH -post hoc (whole cohort) 74 66 
 
73 27 
 
91 9   
Table 7. Comparison of STASH with ISAT and BRAT study.  
Table 7
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A. WFNS grade of patients with aSAH on admission 
 
 
 
B. mRS at discharge 
 
 
 
C. mRS at 6 months 
 
 
 
Figure 1. Distribution of scores for the whole cohort of STASH patients 
stratified by treatment modalities. (A) WFNS admission grade. (B) mRS at 
discharge. (C) mRS at 6 months. mRS= modified Rankin Scale 
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Figure 1
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A. WFNS grade of good grade patients with aSAH on admission  
  
B. mRS at discharge  
  
C. mRS at 6 months  
  
Figure 2. Distribution of scores for the good grade aSAHpatients stratified by 
treatment modalities. (A) WFNS admission grade. (B) mRS at discharge. (C) 
mRS at 6 months. mRS= modified Rankin Scale  
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